PMID- 22045649
OWN - NLM
STAT- MEDLINE
DCOM- 20131216
LR  - 20220330
IS  - 1097-0339 (Electronic)
IS  - 1097-0339 (Linking)
VI  - 41
IP  - 4
DP  - 2013 Apr
TI  - Assessment of estrogen receptor (ER), progesterone receptor (PR), and human 
      epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of 
      metastatic breast carcinomas.
PG  - 308-15
LID - 10.1002/dc.21841 [doi]
AB  - The assessment of estrogen receptor (ER), progesterone receptor (PR) and human 
      epidermal growth factor receptor (HER2) status in the fine needle aspirates of 
      metastatic breast carcinomas has prognostic and therapeutic implications. In this 
      study, expression of ER, PR, and HER2 was assessed by immunohistochemical study 
      in 70 cases of metastatic breast carcinomas and HER2 gene amplification was 
      further evaluated by fluorescence in situ hybridization (FISH) in 38 (54%) cases. 
      Positive expression of ER and PR was seen in 42 (60%) and 16 (23%) cases of 
      metastatic breast carcinomas, respectively. HER2 immunoreactivity was scored as 
      0/1+ in 39 (56%), 2+ in 10 (14%), and 3+ in 21 (30%) cases. HER2 gene 
      amplification was seen in 20% of HER2 2+ and 64% of HER2 3+ cases. ER, PR, and 
      HER2 status in primary breast cancers were available to comparison in 31 cases 
      (44%). The concordance rates between metastatic and primary breast carcinomas 
      were 81% for ER, 65% for PR and 71% for HER2. Our study demonstrates that ER, PR, 
      and HER2 status can be assessed in the fine needle aspirates of metastatic breast 
      carcinomas and ER has a higher concordance rate between metastatic and primary 
      breast carcinomas than PR and HER2. The addition of HER2 gene amplification FISH 
      test helps in accurate assessment of HER2 status in metastatic breast carcinomas.
CI  - Copyright (c) 2011 Wiley Periodicals, Inc.
FAU - Monaco, Sara E
AU  - Monaco SE
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 
      USA.
FAU - Wu, Yue
AU  - Wu Y
FAU - Teot, Lisa A
AU  - Teot LA
FAU - Cai, Guoping
AU  - Cai G
LA  - eng
PT  - Journal Article
DEP - 20111101
PL  - United States
TA  - Diagn Cytopathol
JT  - Diagnostic cytopathology
JID - 8506895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Biopsy, Fine-Needle
MH  - Bone Neoplasms/secondary
MH  - Breast Neoplasms/*pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Liver Neoplasms/secondary
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Progesterone/*metabolism
MH  - Retrospective Studies
MH  - Soft Tissue Neoplasms/secondary
EDAT- 2011/11/03 06:00
MHDA- 2013/12/18 06:00
CRDT- 2011/11/03 06:00
PHST- 2011/04/26 00:00 [received]
PHST- 2011/08/27 00:00 [accepted]
PHST- 2011/11/03 06:00 [entrez]
PHST- 2011/11/03 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
AID - 10.1002/dc.21841 [doi]
PST - ppublish
SO  - Diagn Cytopathol. 2013 Apr;41(4):308-15. doi: 10.1002/dc.21841. Epub 2011 Nov 1.